TauRx Update: HMTM Hong Kong and MacauAn update from TauRx...
https://www.macaubusiness.com/poredeen-appoints-icb-as-exclusive-named-patient-program-manager-for-hmtm-in-hong-kong-and-macau/
"In the United Kingdom, TauRx is actively pursuing approval from the Medicines and Healthcare products Regulatory Agency (“MHRA UK“) through the Innovative Licensing and Access Pathway (“ILAP“). TauRx was granted an Innovation Passport in May 2022, marking the first stage of the approval process, indicating MHRA UK’s recognition of the potential importance of this medication for Alzheimer’s Disease.
TauRx is also submitting the HMTM# results from LUCIDITY and earlier trials for regulatory approval in the USA. TauRx and Poredeen will be meeting and submitting data packages to other drug regulators in more territories, including the People’s Republic of China (“China“), soon."